GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Addex Therapeutics ADXN · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.79

-3.79%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Addex Therapeutics

Its shares trade under the ticker ADXN. It has been listed since 29 January 2020. In the fiscal year to 31 December 2025, it reported revenue of $35,894 and a net loss of $8.1m. At that date it held total assets of $7.6m and shareholders' equity of $5.7m.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Jan 2020
Employees
3
Head office
CHEMIN DES MINES 9, GENEVA, V8, CH-1202
Incorporated in
V8
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Dipraglurant is in phase 1 clinical trials for post-stroke recovery and Parkinson's disease.
  • ADX71149 is currently in phase 1 for an undisclosed medical indication.
  • GABAB PAM targets pain, anxiety, addiction, chronic cough, and overactive bladder.

Weaknesses

  • The company employs only three staff members in its operations.
  • Addex Therapeutics was formerly known as Addex Pharmaceuticals Ltd.
  • The firm is based in Geneva, Switzerland, not the US.

Opportunities

  • A license agreement with Janssen Pharmaceuticals covers mGlu2 PAM compounds.
  • Indivior PLC collaborates on GABAB PAM compounds for addiction treatment.
  • Research focuses on G-protein coupled receptors and enzymes for drugs.

Threats

  • Phase 1 trials for Dipraglurant may face regulatory or safety hurdles.
  • ADX71149 has an undisclosed indication, creating uncertainty about its market potential.
  • Small molecule development for neurological disorders involves high clinical failure risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.